Factsheet - Hepatitis C Treatments (Page 2 of 5) in pdf

Treatment durations

Epclusa

= 12 weeks, irrespective of whether the patient has cirrhosis

Harvoni

= 8 weeks for patients with no prior treatment, no cirrhosis and viral load less than 6 million IU/mL

= 12 weeks for patients with no prior treatment, no cirrhosis and viral load more than 6 million IU/mL

= 12 weeks for patients with no prior treatment and cirrhosis

= 24 weeks for patients with prior treatment and cirrhosis

Sovaldi and Daklinza

= 12 weeks (although likely longer for patients with cirrhosis)

= 24 weeks for patients with genotype 3 and cirrhosis

Sovaldi and Daklinza plus Ibavyr

= 12 weeks for patients with genotype 1 and cirrhosis

= 12 weeks for patients with genotype 3 and cirrhosis

Sovaldi and Ibavyr

= 12 weeks for patients with genotype 2

VIEKIRA PAK

= 12 weeks for patients with genotype 1b, no cirrhosis

= 12 weeks for patients with genotype 1b, compensated cirrhosis

VIEKIRA PAK plus Ibavyr

= 12 weeks for patients with genotype 1a, no cirrhosis

= 12 weeks for patients with genotype 1a, with cirrhosis

= 24 weeks for patients with genotype 1a, cirrhosis and prior null response to treatment

Zepatier

= 12 weeks for patients with genotype 1 or 4, with no prior treatment, or with prior treatment relapse

Zepatier plus Ibavyr

= 16 weeks for patients with genotype 1a or 4, who experienced prior treatment failure.

Are new treatments taken with ribavirin or interferon injections?

Several of the new treatments, listed above, are sometimes taken with ribavirin. Importantly, all the new

treatments are taken as tablets (pills) and none involve interferon injections.

Treatment side effects

Epclusa is well tolerated with only minor side effects.

Harvoni is well tolerated with only minor side effects.

Ibavyr is teratogenic and pregnancy and conception must be strictly avoided (by women AND men) while

on treatment and for 24 weeks following end of treatment.

Sovaldi and Daklinza are well tolerated with only minor side effects.

Sovaldi and Ibavyr are well tolerated – aside from Ibavyr’s teratogenic effects (see below) the most

common adverse events of ribavirin are anaemia, fatigue, headache, skin irritation and insomnia).

Factsheet - Hepatitis C Treatments Page 2